Author/Authors :
Mortaz, Esmaeil Division of Pharmacology - Utrecht Institute for Pharmaceutical Sciences - Faculty of Science - Utrecht University, Utrecht, The Netherlands , Masjedi, Mohammad Reza Chronic Respiratory Diseases Research Center and National Research Institute of Tuberculosis and Lung Diseases (NRITLD) - Department of Immunology - ShahidBeheshti University of Medical Sciences, Tehran , Tabarsi, Payam Clinical Tuberculosis and Epidemiology Research Center - National Research Institute of Tuberculosis and Lung Diseases (NRITLD) - Shahid Beheshti University of Medical Sciences, Tehran , Pourabdollah, Mihan Chronic Respiratory Diseases Research Center and National Research Institute of Tuberculosis and Lung Diseases (NRITLD) - Department of Immunology - ShahidBeheshti University of Medical Sciences, Tehran , Adcock, Ian M. Airways Disease Section - National Heart and Lung Institute - Imperial College London, London, UK
Abstract :
The immunopathology of sarcoidosis remains elusive despite years of research into this
multiorgan disease.However, recent studies have provided new insights into the genetics and
immune components involved in the clinical manifestation of the disease.
Granulomatous inflammation is due to the host immune response to a persistent poorly
degradable unknown antigen.Mycobacterium tuberculosis (MTB) is the major disease driver
in many patients.
The immune mechanisms that cause this disease start with the antigenic stimulus,
followed by T-cell, macrophage and dendritic cell activation via a classic MHC II–mediated
pathway.
In addition, the profile of immune mediators reported in sarcoidosis indicates that the
inflammasome pathway plays a critical role in disease pathogenesis. Increased understanding
of the signal transductions pathways involved in the induction of inflammatory processes in
sarcoidosis could give rise to new therapeutic approaches in future.
